Regulation of Dopamine Transporter Function by G Protein Beta-Gamma Subunits

G 蛋白 β-γ 亚基对多巴胺转运蛋白功能的调节

• 批准号: 9322292
• 负责人: Elias Aizenman
• 金额: $ 40.67万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-15 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9322292
• 关键词: Affect; Amphetamines; Area; Attenuated; Behavior; Behavior Therapy; Behavioral; Binding; Binding Sites; Biochemical; Brain; Brain Diseases; Cells; Clinical; Complex; Corpus striatum structure; Cultured Cells; Data; Dopamine; Drug Addiction; G-protein Beta gamma; G-substrate; GTP-Binding Proteins; Goals; Homeostasis; Intervention; Mediating; Molecular; Motivation; Motor Activity; Phosphorylation; Physiological; Play; Process; Property; Recombinants; Regulation; Research; Rewards; Role; Signal Transduction; Site; Specificity; Synaptic Transmission; Synaptosomes; System; Testing; Therapeutic Uses; Translating; analog; base; dopamine transporter; dopaminergic neuron; extracellular; in vivo; mutant; neuropsychiatric disorder; new therapeutic target; programs; psychostimulant; public health relevance; stimulant abuse; uptake

DESCRIPTION (provided by applicant): The dopamine transporter (DAT) plays a crucial role in the regulation of brain dopamine (DA) homeostasis. Through re-uptake of DA, DAT serves two important functions: the termination of synaptic transmission at dopaminergic terminals, and the replenishment of vesicular DA pools. In addition to uptake or direct transport, DAT can also function to release DA. This process, which is referred to as reverse transport or efflux, is the mechanism used by potent and highly addictive psychostimulants, such as amphetamine and its analogues, to increase extracellular DA levels in motivational and reward areas of the brain. It has long being recognized that DA neurons release DA through exocytotic and non-exocytotic processes. However, the exact mechanism by which physiological signals or psychostimulants, such as amphetamine, induce DA release through DAT still remains a complex and not completely understood area of research. Thus, examining the basic mechanism(s) that affect reverse transport through DAT is critical for both understanding fundamental aspects of DA regulation and clinical intervention in DA-related brain disorders associated with the therapeutic use and abuse of psychostimulants. The long-term goal of our research program is to identify and characterize signaling mechanisms that control DA release through DAT, and elucidate the molecular actions of psychostimulants. This application is based on our recent discovery that the beta upsilon subunit of G proteins (Gbetagamma) binds DAT and regulates transporter activity. This effect was demonstrated in cultured cells, brain synaptosomes, and in vivo. More importantly, activation of Gbetagamma promotes DAT-mediated DA efflux, whereas inhibition of Gbetagamma attenuates amphetamine-elicited DA efflux in cultured cells. Finally, activation of Gbetagamma enhances whereas inhibition of Gbetagamma reduces amphetamine-evoked locomotor activity in vivo. Based on these preliminary data, the central hypothesis of this proposal is that the interaction between DAT and beta upsilon subunits promotes DA release through DAT and is involved in the actions of amphetamine. In this proposal we will i) identify the Gbetagamma interaction site(s) in DAT and their role in transporter regulation, ii) test the hypothesis that Gbetagamma is involved in DAT-mediated DA efflux, and iii) test the hypothesis that Gbetagamma is involved in amphetamine's actions in vivo. The successful completion of the studies proposed here will provide a detailed characterization of the DAT-Gbetagamma interaction and a clear understanding of its contribution to DAT reverse transport. The fact that amphetamine induces DAT reversal suggests that DA can also be released through DAT under physiological conditions. Therefore, our proposed studies will define not only the role that Gbetagamma subunits play in the addictive properties of amphetamine, but also the contribution of Gbetagamma subunits to DA homeostasis as we grow our current understanding of the molecular details underlying physiological DAT reverse transport. The long-term goal of our research program is to identify novel therapeutic targets that can be used in the treatment of neuropsychiatric disorders, including drug addiction.

描述（由申请人提供）：多巴胺转运蛋白（DAT）在脑多巴胺（DA）稳态调节中起关键作用。通过DA的再摄取，DAT具有两个重要功能：终止多巴胺能末梢的突触传递和补充囊泡DA池。除了摄取或直接运输，DAT也可以释放DA。这个过程被称为反向运输或外排，是强效和高度成瘾性精神兴奋剂（如安非他明及其类似物）用于增加大脑动机和奖励区域细胞外DA水平的机制。DA神经元通过胞吐和非胞吐两种方式释放DA。然而，生理信号或精神兴奋剂（如安非他明）通过DAT诱导DA释放的确切机制仍然是一个复杂且尚未完全理解的研究领域。因此，检查通过DAT影响反向转运的基本机制对于理解DA调节的基本方面和与精神兴奋剂的治疗使用和滥用相关的DA相关脑疾病的临床干预至关重要。我们研究计划的长期目标是确定和表征通过DAT控制DA释放的信号机制，并阐明精神兴奋剂的分子作用。这项应用是基于我们最近的发现，即G蛋白的β-uptagamma亚基（G β γ）结合DAT并调节转运蛋白活性。这种效应在培养的细胞、脑突触体和体内都得到了证实。更重要的是，在培养的细胞中，G β γ的激活促进DAT介导的DA外排，而G β γ的抑制减弱安非他明引起的DA外排。最后，在体内，激活Gbetagamma增强而抑制Gbetagamma减少安非他明诱发的运动活性。基于这些初步的数据，这个建议的中心假设是，DAT和β-uppertin亚基之间的相互作用，促进DA释放通过DAT和参与安非他明的行动。在这个提议中，我们将i）鉴定DAT中的G β γ相互作用位点及其在转运蛋白调节中的作用，ii）检验G β γ参与DAT介导的DA外排的假设，和iii）检验G β γ参与安非他明体内作用的假设。这里提出的研究的成功完成将提供详细的特性的DAT-γ相互作用，并清楚地了解其对DAT反向运输的贡献。安非他明诱导DAT逆转的事实表明，DA也可以通过DAT在生理条件下释放。因此，我们提出的研究将不仅定义的作用，Gbetagamma亚基在苯丙胺的成瘾性，但也贡献Gbetagamma亚基DA稳态，因为我们增长我们目前的理解生理DAT反向运输的分子细节。我们研究计划的长期目标是确定可用于治疗神经精神疾病（包括药物成瘾）的新治疗靶点。